期刊文献+

抗器官排斥药物和方案对器官移植术后血脂变化的影响 被引量:2

Effects of different anti-rejection drugs and projects on dyslipidemia after organ transplantation
原文传递
导出
摘要 器官移植术后血脂异常是器官移植术后心血管疾病及移植物失功的重要危险因素之一。影响器官移植术后血脂变化的因素很多,然而随着器官移植的发展,不同年代影响术后血脂变化的因素也有所改变。本文综述了不同年代抗器官排斥药物包括环孢素、硫唑嘌呤、霉酚酸酯、他克莫司、雷帕霉素(西罗莫司)、激素以及单抗等免疫抑制剂应用的不同对术后受者血脂的影响。 [Summary] Dyslipidemia after organ transplantation is one of the important risk factors of postoperative cardiovascular disease and graft dysfunction. There are many factors that result in postoperative dyslipidemia. However, the factors influencing serum lipid levels are changing with the development of organ transplantation. In this article the effects of different anti-rejection drugs such as cyclosporine, azathioprine, mycophenolate mofetil, tacrolimus, rapamycin ( sirolimus ) , corticosteroids, and monoclonal antibody on dyslipidemia after organ transplantation were summarized in different eras.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2015年第9期816-818,共3页 Chinese Journal of Endocrinology and Metabolism
关键词 不同年代 器官移植 抗排斥药物 血脂异常 Different eras Organ transplantation Anti-rejection drugs Dyslipidemia
  • 相关文献

参考文献26

  • 1Lv C, Chen M, Xu M, et al. Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate[ J]. PLoS One, 2014,9(6) :e99406.
  • 2Mareen R. Immunosuppressive drugs in kidney transplantation : impact on patient survival, and incidence of cardiovascular disease, malignancy and infection [ J ]. Drugs, 2009,69 ( 16 ) :2227-2243.
  • 3Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients[ J]. Am Heart J, 2004, 148(2) :200-210.
  • 4Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyelosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis [ J ]. Transplantation, 2003,76 ( 2 ) :375-382.
  • 5Akhlaghi F, Jackson CH, Parameshwar J, et at. Risk factors for the development and progression of dyslipidemia after heart transplantation [ J ]. Transplantation, 2002,73 ( 8 ) : 1258-1264.
  • 6Akman B, Uyar M, Afsar B, et al. Lipid profile during azathioprine or myeophenolate mofetil combinations with cyclosporine and steroids [ J ]. Transplant Proc, 2007,39 ( 1 ) :135-137.
  • 7Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trim of tacrolimus/prednisone vs tacrolimus/prednisone/ mycophenolate mofctil in renal transplantation : 1 -year actuarial follow- up [J].Transplant Proc, 1999,31 ( 1-2 ) : 1134.
  • 8Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients : focus on the cardiovascular risk [J ]. Drugs, 2004,64 ( 18 ) : 2047-2073.
  • 9Krok KL, Thuluvath PJ. Perioperative and postoperative use of immunosuppressive agents in liver transplantation [ J ]. Int Anesthesiol Clin, 2006,44 ( 3 ) :51-68.
  • 10Deleuze S, Garrigue V, Delmas S, et al. New onset dyslipidemia after renal transplantation: Is there a difference between tacrolimus and cyclosporine [ J ] ? Transplant Proe, 2006,38 ( 7 ) : 2311-2313.

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部